Five9 (FIVN) Q2 Revenue Jumps 12%
GAAP revenue rose 12% year over year to $283.3 million in Q2 2025, surpassing analyst estimates by $8.1 million.
Non-GAAP earnings per share reached $0.76, beating expectations by $0.14 (non-GAAP) and up from $0.52 per diluted share (non-GAAP) in Q2 2024.
Enterprise AI revenue grew 42% year-over-year, now accounting for 10% of enterprise subscription revenue.
These 10 stocks could mint the next wave of millionaires ›
Five9 (NASDAQ:FIVN), a provider of cloud-based contact center software, released its second quarter earnings for fiscal 2025 on July 31, 2025.
Five9 posted GAAP revenue of $283.3 million for Q2 2025, up 12% from the prior year period.
, coming in $8.1 million ahead of analyst expectations. Non-GAAP earnings per share were $0.76, well above the $0.62 analyst forecast (non-GAAP). Five9 highlighted accelerated growth in its Enterprise AI segment, with Enterprise AI revenue increasing 42% year-over-year, achieving a record adjusted EBITDA margin and improved operating cash flow, despite some macroeconomic caution and a sequential dip in its key net retention metric, with LTM dollar-based retention rate at 107% versus 108% in the prior quarter. Overall, the quarter showed broad-based improvement and momentum in both financial and operational metrics.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (Non-GAAP) $0.76 $0.62 $0.52 46.2%
Revenue $283.3 million $275.2 million $252.1 million 12.4%
Gross Margin 54.9% 53.0% 1.9 pp
Gross Margin (Non-GAAP) 63.0% 60.5% 2.5 pp
Adjusted EBITDA Margin 24.0% 16.6% 7.4 pp
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Business Overview and Strategic Focus
Five9 operates in the software-as-a-service space, specifically providing cloud-based call center platforms for businesses shifting away from traditional, on-premises systems. Its main product allows organizations to manage phone, chat, email, and other customer interactions in a single platform. The system is designed to replace legacy hardware with scalable, flexible solutions that enable remote work and seamless customer engagement across digital channels.
In recent years, Five9's key areas of focus have included driving adoption of its cloud solutions, accelerating advancements in Artificial Intelligence, supporting digital transformation for clients, and extending its partner ecosystem. These strategies are vital for capturing market share as companies modernize their customer-facing operations. Enterprise migration to the cloud, integration of advanced AI features, and deeper relationships with global partners have become central to Five9's growth and ongoing relevance in a rapidly changing market.
Quarter Highlights and Notable Developments
During Q2 2025, Five9 substantially outperformed its financial guidance and market estimates, with non-GAAP EPS of $0.76 exceeding the analyst estimate of $0.62 and GAAP revenue of $283.3 million surpassing the analyst estimate of $275.17 million. It reported a significant revenue increase, a record high in adjusted EBITDA margin (24.0% non-GAAP), and stronger free cash flow. Non-GAAP earnings were higher than expected, reflecting improved operating efficiency and a favorable revenue mix shift toward subscription and AI-driven services. These results marked the company's best quarter yet for both operating and free cash flow.
AI revenue in the enterprise market rose 42% year-over-year and now accounts for 10% of enterprise subscription revenue. Management reported that Enterprise AI bookings more than tripled year-over-year, and more than 20% of new large enterprise deals included AI solutions in Q1 2025. Product launches this quarter included new Agentic AI Agents and Trust & Governance tools, both part of the Genius AI suite. These products use machine learning and generative AI to improve call handling and oversight, offering customers real savings and operational improvements.
Subscription revenue -- the portion of revenue tied to ongoing platform usage -- grew by 16% year-over-year. This growth, combined with strong uptake of AI and multi-channel capabilities, improved both GAAP and non-GAAP gross margins and overall profitability. Five9 attributed much of the margin expansion in Q1 2025 to this revenue mix shift and to disciplined cost controls, including a workforce reduction earlier in the year that is expected to save $20–$25 million in annual compensation-related non-GAAP expense. These savings are now being reinvested in high-priority areas such as AI development and go-to-market (sales and marketing) initiatives.
The company's partnerships and channel strategies played a significant role in the quarter. Integrations with enterprise software providers such as Salesforce, Microsoft, ServiceNow, and IBM are expanding Five9's reach and enabling joint sales wins, especially in financial services, healthcare, and vehicle mobility. Management noted some resistance to U.S. vendors in international regions during the Q1 2025 earnings call and took a conservative view on international growth for the remainder of 2025.
Regarding specific products, Five9's Agentic AI Agents are virtual representatives powered by artificial intelligence, designed to automate both self-service and assist live agents. The Genius AI suite includes applications for speech recognition, automated insights, and conversation summaries. Five9 Fusion, its integration for Salesforce users, enables enterprise clients to use Five9's voice services alongside CRM data in a unified workflow, further enhancing digital transformation.
Looking Ahead: Guidance and Watch Points
Management's guidance for Q3 2025 is revenue between $283.0 million and $286.0 million, essentially flat from Q2 2025. Full-year 2025 revenue guidance remains $1.1435 billion to $1.1495 billion, reflecting a prudent approach given current economic conditions and some lengthening of large deal sales cycles. For earnings, the company projects GAAP diluted EPS of $0.06 to $0.12 for Q3 2025 and $0.23 to $0.30 for the full year; Non-GAAP EPS guidance is $0.72 to $0.74 for Q3 2025 and $2.86 to $2.90 for FY2025. Management cited high visibility into the installed customer base as supporting the stability of these forecasts. About 93% of incremental recurring revenue expected in the 2025 outlook is planned to come from existing clients, not new wins.
There is also some risk noted on international deals and go-to-market execution, as well as a significant drop in cash and marketable investments from $362.5 million and $643.4 million as of December 31, 2024, to $205.5 million and $430.4 million as of June 30, 2025, following debt repayment. Continued success in AI product adoption and further penetration of new and existing enterprise clients will be important to monitor. Five9 does not currently pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 29, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
2 hours ago
- Globe and Mail
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
2 hours ago
- Globe and Mail
Ambiq Micro's IPO Could Signal the Next Wave of AI-Driven Chip Stocks
Key Points Ambiq Micro debuted to much fanfare on the first day of trading following its highly touted IPO. The company is a pioneer in ultra-low-power semiconductors used at the edge. While Ambiq Micro's future looks bright, that are potential risks investors shouldn't ignore. 10 stocks we like better than Ambiq Micro › Since generative artificial intelligence (AI) burst on the scene more than two years ago, some of the biggest beneficiaries have been chipmakers. More specifically, advanced semiconductors provide the computational horsepower necessary to breathe life into these AI algorithms. Nvidia, Broadcom, and Arm Holdings have all been at the forefront of AI chip design and reaped the rewards. Nvidia and Broadcom stocks have soared 961% and 439%, respectively, since late 2022, while Arm has gained 173% since its September 2023 initial public offering (IPO). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Ambiq Micro (NYSE: AMBQ) made a big splash during its public debut, as the low-power chip designer's stock surged 61% on its first day of trading last Wednesday, though it has since leveled off. Investors have been keen to profit from the ongoing adoption of AI, and the robust demand for Ambiq Micro stock suggests that power-miserly AI chip stocks could mark the next frontier. The power conundrum One of the biggest challenges associated with the increasing adoption of AI is the issue of power consumption. Most chipmakers have taken a brute-force approach, increasing the sheer magnitude of computational horsepower to decrease the time necessary to train and run these next-generation algorithms. The complex calculations required are computationally intensive, resulting in an increasing amount of energy consumption. Ambiq is taking a different approach. In the S-1 filed with the Securities and Exchange Commission (SEC) prior to its IPO, the company described itself as a "pioneer and leading provider of ultra-low-power semiconductor solutions designed to address the significant power consumption challenges of general-purpose and AI compute -- especially at the edge." Ambiq suggests its hardware and software innovations "deliver two to five times lower power consumption than traditional semiconductor design." The company is currently focused on the edge, including personal devices, as well as the medical and healthcare industries. Many of these applications are currently handled by small devices with limited battery life, where reduced power consumption is critical. In the future, Ambiq is working to expand its ultra-low-power technology to other areas of AI, including high-performance computing (HPC), data centers, and automotive, which could mark the next wave of AI chip solutions. A growing opportunity The need for power-miserly solutions could usher in the next wave of AI chips, and Ambiq's results are intriguing. For the year ended Dec. 31, the company generated revenue of $76 million, up 16% year over year, while its loss per share of $113.81 improved 24%. The trend continued in the quarter ended March 31, as revenue of $15.7 million climbed 3%, while its loss per share of $18.96 improved 30%. There is a significant concentration risk. Ambiq divulged that its top five customers accounted for 92% of revenue in the most recent quarter. Furthermore, wireless device specialist Garmin, Alphabet 's Google, and "another confidential customer" represented 38%, 25%, and 23% of net sales, respectively, according to its regulatory filing. Ambiq's flagship system-on-a-chip (SoC) is designed for smaller form-factor devices, such as smartwatches, fitness trackers, hearing aids, virtual and augmented reality glasses, and livestock tracking devices. Chief technology officer (CTO) Scott Hanson noted the company's next frontier is smart glasses. "We spent the last 10-plus years figuring out how to build the lowest power chips, and so we're in a great position to attack the same problem (on glasses)," he said. The low-power wearable chips market is expected to grow by 15% annually between 2024 and 2030 to nearly $28 billion. When viewed in the context of Ambiq's 2024 sales of $76 million, the opportunity is apparent. Every rose has its thorns It's important to remember that while Ambiq's potential is clear, risks abound. It has only just entered the glare of the public spotlight, and investors should keep in mind the aforementioned concentration risk and mounting losses, though its results are moving in the right direction. There's also the matter of Ambiq's valuation. As of market close on Monday, the stock had a market cap of roughly $673 million and trailing-12-month sales of $76.6 million. That works out to about 9 times sales, and while that's certainly not outrageous, it is a high price to pay for an unprofitable company with little public track record. As such, investors interested in taking a stake in this ultra-low-power pioneer should make Ambiq a small part of a well-balanced portfolio. Should you invest $1,000 in Ambiq Micro right now? Before you buy stock in Ambiq Micro, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ambiq Micro wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* *Stock Advisor returns as of August 4, 2025
